2017 年 34 巻 3 号 p. 288-292
Dominantly Inherited Alzheimer Network (DIAN), Dominantly Inherited Alzheimer Network Trial Unit (DIAN–TU), and DIAN–Japan were reviewed. In Japan, participants enrolment is initiated from 2016. These global studies would contribute to clarify the signature of Alzheimer's pathology and validity of biomarkers. These studies now move to clinical trials for prevention of Alzheimer's disease. Thus, strong evidences from DIAN and DIAN–TU are now getting hot attentions and their desirable contribution are waiting.
